SCHEMBL2183273

SCHEMBL2183273

O=c1[nH]c(=O)n(C(c2ccccc2)c2ccccc2)cc1/C=C/[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.53
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 7/20 0.40
NPSR1 Q6W5P4 6/20 0.40
ALDH1A1 P00352 5/20 0.40
HTT P42858 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 2/20 0.40
HSP90AA1 P07900 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
FBP1 P09467 1/20 0.40
MET P08581 5/20 0.39
TLR4 O00206 2/20 0.38
TLR2 O60603 2/20 0.38
RXRA P19793 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1558317 1.00 GAA (0.53) GAAMEN1KMT2AMAPTNPSR1
SCHEMBL12410825 0.88 MET (0.54) GAAMEN1KMT2AMAPTNPSR1
SCHEMBL12410795 0.82 GAA (0.64) GAAMEN1KMT2ANPSR1CYP1A2
SCHEMBL17243356 0.81 GAA (0.58) GAAMEN1KMT2AMET
SCHEMBL12499643 0.81 GAA (0.58) GAAMEN1KMT2AATMMET
SCHEMBL12495880 0.79 GAA (0.56) GAAMEN1KMT2AATMSMN1; SMN2
SCHEMBL17243371 0.78 GAA (0.55) GAAMEN1KMT2AMET
SCHEMBL1558603 0.78 GAA (0.55) GAAMEN1KMT2ASMN1; SMN2MET
SCHEMBL1558602 0.78 GAA (0.55) GAAMEN1KMT2ASMN1; SMN2MET
SCHEMBL12410771 0.76 GAA (0.62) GAAMEN1KMT2AALDH1A1MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181199-B2 Uracil derivatives and use thereof RESPROTECT GMBH (DE) 2015-11-10 US disclosed
US-9181199-B2 Uracil derivatives and use thereof RESPROTECT GMBH (DE) 2015-11-10 US disclosed
US-9181199-B2 Uracil derivatives and use thereof RESPROTECT GMBH (DE) 2015-11-10 US disclosed
US-20110166096-A1 URACIL DERIVATIVES AND USE THEREOF RESPROTECT GMBH (DE) 2011-07-07 US disclosed
US-20110166096-A1 URACIL DERIVATIVES AND USE THEREOF RESPROTECT GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166096-A1 URACIL DERIVATIVES AND USE THEREOF TYMP, UNG, DPYD GAA 2007/4885MEN1 2207/4885KMT2A 3185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.